Guanylate Cyclase
Guanylate cyclase (guanylyl cyclase, GC), which catalyzes the formation of cGMP from GTP, exists in both the soluble and particulate fractions of cells. Guanylyl cyclases signal via the production of the second messenger cGMP.
The GC family consists of particulate GC (pGC) and a nitric oxide-activated soluble GC (sGC). Seven pGC isoforms have yet been found (pGC-A to pGC-G). pGCs are activated by binding of peptide ligands to their extracellular domains. sGC is a receptor for endogenous and exogenous nitric oxide and is activated several-fold upon its binding, constituting a core enzyme in the nitric oxide signal transduction pathway. cGMP generated by sGC is an important second messenger that regulates activity of several enzymes triggering such important physiologic reactions as vasodilation, smooth muscle relaxation and platelet aggregation.
All Product Categories
-
Guanylate Cyclase Inhibitors
(19)
View all products
-
Guanylate Cyclase Agonists
(12)
View all products
-
Guanylate Cyclase Activators
(59)
View all products
-
Guanylate Cyclase Modulators
(2)
View all products
-
Guanylate Cyclase Inducer
(1)
View all products
-
Guanylate Cyclase Control
(1)
View all products
-
Guanylate Cyclase Related Products (101)
Related Products (101)
-
Antibodies (2)
-
CFM 1571 hydrochloride (Standard)
0 ImagesCat. No.: HY-107546RCAS No.: 1215548-30-3CFM 1571 hydrochloride (Standard) is the analytical standard of CFM 1571 (hydrochloride) (HY-107546). This product is intended for research and analytical applications. CFM 1571 hydrochloride is the stimulator of the nitric oxide receptor, soluble guanylate cyclase (sGC) with an EC50 and IC50 of 5.49 μM and 2.84 μM, respectively. Soluble guanylate cyclase (sGC) is a key signal-transduction enzyme activated by nitric oxide (NO). CFM 1571 hydrochloride has the potential for the research of cardiovascular and other diseases.
-
SE 175
0 ImagesCat. No.: HY-120221CAS No.: 258278-64-7SE 175 is an organic nitrate compound that acts as an NO donor in vivo following reductive transformation of the nitrate group to nitric oxide. SE 175 stimulates endothelial soluble guanylate cyclase and induces aortic vasorelaxation with an EC50 of 0.20 µM.
-
Praliciguat (Standard)
0 ImagesCat. No.: HY-109039RCAS No.: 1628730-49-3Synonyms: IW-1973 (Standard)Praliciguat (Standard) is the analytical standard of Praliciguat (HY-109039). This product is intended for research and analytical applications. Praliciguat (IW-1973) is a potent and orally active soluble guanylate cyclase (sGC) activator. Praliciguat can increases cGMP via the nitric oxide (NO)-sGC pathway. Praliciguat can inhibit the expression of proinflammatory cytoKines and inhibit apoptosis. Praliciguat can promote vasodilation. Praliciguat can be used for the researches of metabolic disease and cardiovascular disease, such as hypertension, diabetes and heart failure.
-
Runcaciguat (Standard)
0 ImagesCat. No.: HY-109136RCAS No.: 1402936-61-1Synonyms: BAY 1101042 (Standard)Runcaciguat (Standard) is the analytical standard of Runcaciguat (HY-109136). This product is intended for research and analytical applications. Runcaciguat (BAY 1101042) is a selective, orally active, allosteric activator of soluble guanylate cyclase (sGC) that specifically targets its oxidized and heme-free form. Runcaciguat binds to sGC in a histidine-dependent manner and restores cyclic guanosine monophosphate (cGMP) production under oxidative stress, independent of nitric oxide (NO) or heme. Runcaciguat exhibits renoprotective and cardioprotective activities, such as reduced proteinuria and improved renal function. Runcaciguat is primarily being studied in chronic Kidney disease (CKd) associated with hypertension, diabetes, and metabolic disorders, as well as potential cardiovascular indications such as heart failure with preserved ejection fraction (HFpEF).
-
IWP-051
0 ImagesCat. No.: HY-117443CAS No.: 1354041-91-0IWP-051 is an agonist for soluble guanylate cyclase with an EC50 of 290 nM. IWP-051 stimulates the generation of cGMP, and exhibits the synergistic effect with NO. IWP-051 exhibits good pharmacokinetic characteristics in rats.
-
2-Chloro-ATP
0 ImagesCat. No.: HY-137325CAS No.: 49564-60-52-Chloro-ATP is a soluble guanylate cyclase inhibitor that increases intracellular calcium concentration at low concentrations through a mechanism independent of inositol phosphate production.
-
Riociguat-d3
0 ImagesCat. No.: HY-14779S3CAS No.: 1304478-72-5Synonyms: BAY 632521-d3Riociguat-d3 (BAY 632521-d3) is deuterium labeled Riociguat. Riociguat is an oral stimulator of soluble guanylate cyclase (sGC) used in the treatment of pulmonary hypertension.
-
Olinciguat (Standard)
0 ImagesCat. No.: HY-109066RCAS No.: 1628732-62-6Synonyms: IW-1701 (Standard)Olinciguat (Standard) is the analytical standard of Olinciguat (HY-109066). This product is intended for research and analytical applications. Olinciguat (IW-1701) is an oral guanylate cyclase (sGC) stimulator with concentration-dependent stimulation of sGC in purified rat and human enzyme assays and a whole cell assay.
-
A-350619
0 ImagesCat. No.: HY-136781CAS No.: 538368-27-3A-350619 is a novel sGC activator. A-350619 increases intracellular cGMP levels. A-350619 significantly induces penile erection.
-
Lificiguat (Standard)
0 ImagesSynonyms: YC-1 (Standard)Lificiguat (Standard) is the analytical standard of Lificiguat. This product is intended for research and analytical applications. Lificiguat binds to the β subunit of soluble guanylyl cyclase(sGC) with Kd of 0.6-1.1 μM in the presence of CO.
-
Vericiguat impurity-3
0 ImagesCat. No.: HY-164228Vericiguat impurity-3 is an impurity of Vericiguat (HY-16774). Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
-
Vericiguat (Standard)
0 ImagesSynonyms: BAY1021189 (Standard)Vericiguat (Standard) is the analytical standard of Vericiguat. This product is intended for research and analytical applications. Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
-
A-350619 hydrochloride
0 ImagesCat. No.: HY-107548CAS No.: 1217201-17-6A-350619 hydrochloride is a soluble guanylate cyclase (sGC) activator. A-350619 hydrochloride can be used in the study of erectile dysfunction.
-
Vericiguat-d6
0 ImagesCat. No.: HY-16774S2Synonyms: BAY1021189-d6Vericiguat-d6 (BAY1021189-d6) is deuterium labeled Vericiguat. Vericiguat (BAY1021189) is a potent, orally available and soluble guanylate cyclase stimulator.
-
BNN5Na
0 ImagesCat. No.: HY-W698583ACAS No.: 214211-69-5BNN5Na is a guanylate cyclase activator and vasorelaxant inducer. BNN5Na undergoes photolytic uncaging to release nitric oxide. BNN5Na remains stable in pH 7.4 phosphate buffer at 37°C for over 1 day in the dark and does not react noticeably with cysteine under these conditions. BNN5Na is water-soluble but membrane-impermeant, remaining in extracellular aqueous compartments. BNN5Na shows no cytotoxicity toward rat aortic strip contractile apparatus.
-
BAY 41-2272 (Standard)
0 ImagesBAY 41-2272 (Standard) is the analytical standard of BAY 41-2272. This product is intended for research and analytical applications. BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research.
-
NMI-1182
0 ImagesCat. No.: HY-189119CAS No.: 646509-43-5NMI-1182 is a nitric oxide-releasing prodrug of Naproxen (HY-15030). NMI-1182 is an orally active COX-1 and COX-2 inhibitor. NMI-1182 inhibits constitutive COX-1-mediated and inducible COX-2-mediated prostaglandin synthesis. NMI-1182 induces nitric oxide donor release, activating soluble guanylate cyclase to synthesize cGMP, causing vasodilation. NMI-1182 can be used for research on inflammation and pain.
-
Linaclotide (Standard)
0 ImagesCat. No.: HY-17584RCAS No.: 851199-59-2Linaclotide (Standard) is the analytical standard of Linaclotide. This product is intended for research and analytical applications. Linaclotide is a potent and selective guanylate cyclase C agonist; developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation.
-
LY83583 (Standard)
0 ImagesLY83583 (Standard) is the analytical standard of LY83583 (HY-W013386). This product is intended for research and analytical applications. LY83583 is inhibitor of soluble guanylate cyclase (sGC) with the ability to target the cGMP signaling pathway. LY83583 inhibits the kinase activity-related proliferation of tumor cells by inducing the Cdk inhibitor p21. LY83583 can be used for the study of cancers (colorectal cancer, breast cancer and melanoma) and cardiovascular disease.
-
Cinaciguat hydrochloride (Standard)
0 ImagesSynonyms: BAY 58-2667 hydrochloride (Standard)Cinaciguat (hydrochloride) (Standard) is the analytical standard of Cinaciguat (hydrochloride). This product is intended for research and analytical applications. Cinaciguat hydrochloride is a potent soluble guanylate cyclase (GC) activator with EC50 of 15 nM in platelets.
